Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 112Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 85Glioblastoma 72Ovarian Neoplasms 62Brain Neoplasms 45Lung Neoplasms 41Glioma 41Fallopian Tube Neoplasms 41Neoplasms 38Colonic Neoplasms 34Gliosarcoma 33Carcinoma, Renal Cell 32Rectal Neoplasms 31Neoplasm Metastasis 29Pancreatic Neoplasms 19Carcinoma, Hepatocellular 19Melanoma 18Adenocarcinoma of Lung 18Astrocytoma 15Kidney Neoplasms 13Stomach Neoplasms 12Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Oligodendroglioma 11Liver Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Adenocarcinoma, Bronchiolo-Alveolar 10Central Nervous System Neoplasms 9

Interventions

carotuximab 1Gemcitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adult Solid Tumor × Bevacizumab × Clear all
NCT01332721 2018-12-05

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Tracon Pharmaceuticals Inc.

Phase 1 Completed
38 enrolled 8 charts
Other solid neoplasm

Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡